NCT05994300

Moderately Hypofractionated Adaptive Radiotherapy for Cervical Cancer

Clinical Research of Moderately Hypofractionated Radiotherapy for Cervical Cancer

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Peking Union Medical College Hospital · Academic / Other
• Sex: Female
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

External radiation given in 25 fractions or so together with weekly chemotherapy and followed by 5 or 6 fractions of brachytherapy is the standard of care for patients with locally advanced cervical cancer. We hope to develop external moderately hypofractionated radiotherapy of cervical cancer based on adaptive radiotherapy.The objective of this study is to evaluate the efficacy and treatment-related toxicity of moderately hypofractionated adaptive radiotherapy in the treatment of cervical cancer.

Detailed description

This is an investigator-initiated efficacious, single-center, open-label clinical trial study. This study hypothesizes that the use of external moderately hypofractionated radiotherapy of cervical cancer based on adaptive radiotherapy. A dose of 43.35Gy in 17 fractions is delivered to clinical target volume (CTV). Patients receive cisplatin based concurrent chemotherapy. The primary endpoint is acute toxicity.

Conditions

• Cervical Neoplasm
• Adaptive Radiotherapy
• Radiotherapy; Adverse Effect

Interventions

Type	Name	Description
RADIATION	Moderately hypofractionated adaptive radiotherapy (ART)+ High-dose rate (HDR) Brachytherapy	Experimental: 43.35Gy/17F external beam radiotherapy (EBRT) with adaptive radiotherapy (ART) + HDR-Brachytherapy Drug: Concurrent Chemotherapy Weekly cisplatin 40 mg/m2

Timeline

• Start date: 2023-09-19
• Primary completion: 2024-07-22
• Completion: 2025-12-31
• First posted: 2023-08-16
• Last updated: 2025-06-08

Locations

1 site across 1 country: China